Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 408.18 USD 0.72% Market Closed
Market Cap: 105.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is 264.48 USD. Compared to the current market price of 408.18 USD, Vertex Pharmaceuticals Inc is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
Base Case
264.48 USD
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.9
P/S
P/S
Price to Sales
9.9
vs History
42
vs Industry
41
Median 3Y
9.4
Median 5Y
9.5
Industry
7.6
Forward
9.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
6
Median 3Y
25
Median 5Y
25.6
Industry
22.1
Forward
683.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
6
Median 3Y
20.7
Median 5Y
21.9
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
5
Median 3Y
22.3
Median 5Y
23.9
Industry
23.4
More Details
6.7
P/B
P/B
Price to Book Value
6.7
vs History
33
vs Industry
12
Median 3Y
6
Median 5Y
6.3
Industry
2.5
More Details
9.1
EV/S
EV/S
Enterprise Value to Sales
9.1
vs History
38
vs Industry
36
Median 3Y
8.2
Median 5Y
8.4
Industry
7.5
Forward
8.7
More Details
10.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.6
vs History
38
vs Industry
31
Median 3Y
9.3
Median 5Y
9.6
Industry
9.3
More Details
21.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.6
vs History
34
vs Industry
4
Median 3Y
19.4
Median 5Y
19.4
Industry
4.2
Forward
73.6
More Details
22.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
22.7
vs History
34
vs Industry
4
Median 3Y
20.2
Median 5Y
20.4
Industry
4
Forward
146.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
5
Median 3Y
18.1
Median 5Y
19.2
Industry
5.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
5
Median 3Y
19.2
Median 5Y
20.3
Industry
3.9
More Details
9.3
EV/IC
EV/IC
Enterprise Value to IC
9.3
vs History
60
vs Industry
23
Median 3Y
9.1
Median 5Y
9.8
Industry
4.5
More Details

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD 9.9 -219.3 21.6 22.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
317.9B USD 5.7 62.5 15.5 23.9
US
Amgen Inc
NASDAQ:AMGN
141.7B USD 4.4 33.6 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 4.1 928.1 10.3 10.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.3 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 5.7 16.9 15.3 17
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.3 -109.3 -79.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.3B USD 14.9 -94.2 -223.6 -157.1
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/S: 3 467 701.5
9.9
34%
0.3
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
96%
0.2
P/E Multiple
Earnings Growth P/E to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 214.6
Negative Multiple: -219.3
48%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.5
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.6
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
928.1
77%
12
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -94.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 16.4
21.6
43%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -223.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 21.5
22.7
45%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -157.1 N/A N/A

See Also

Summary
VRTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRTX stock valuation using valuation multiples.
Wall Street Estimates
VRTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.